FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092183118> ?p ?o ?g. }

• W2092183118 endingPage "174" @default.
• W2092183118 startingPage "171" @default.
• W2092183118 abstract "Multiple myeloma (MM) is a malignant disease characterized by the clonal proliferation of plasma cells within the bone marrow. Several cytokines have been demonstrated to be involved in the control of growth, progression, and dissemination of MM. We determined serum levels of interleukin-1beta (IL-1beta), soluble interleukin-2 receptor (sIL-2R), interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-alpha), and C-reactive protein (CRP) in 14 newly diagnosed MM patients. The median age of the patients was 63.4 +/- 10.8 years and all of the patients were stage III (classified according to the Durie-Salmon classification). The same parameters were measured in 15 healthy controls. In addition, we also examined the effects of vincristine-adriamycin-dexamethasone (VAD) therapy on the same parameters and mediators as well as the relationship among the parameters in the same patient groups. The serum concentrations of TNF-alpha, IL-1beta, sIL-2R, IL-6, IL-8, and CRP (18.6 +/- 3.7 pg/mL, 10.1 +/- 2.8 pg/mL, 730 +/- 220 U/mL, 11.4 +/- 3.3 pg/mL, 23.9 +/- 8.3 pg/mL, and 49.9 +/- 19.5 mg/dL, resp) were significantly higher in newly diagnosed MM patients than in healthy controls (P < .0001). All of the parameters were found to be significantly reduced after chemotherapy. In conclusion, we found that after the VAD therapy, the level of these cytokines which are thought to play an important role in the pathogenesis of MM was significantly suppressed. This is the first study demonstrating strong impact of VAD treatment on circulating mediators of sIL-2R and IL-8 levels parameters." @default.
• W2092183118 created "2016-06-24" @default.
• W2092183118 creator A5008969241 @default.
• W2092183118 creator A5022059136 @default.
• W2092183118 creator A5032698656 @default.
• W2092183118 creator A5034207640 @default.
• W2092183118 creator A5035767817 @default.
• W2092183118 creator A5039810213 @default.
• W2092183118 creator A5077108549 @default.
• W2092183118 date "2005-01-01" @default.
• W2092183118 modified "2023-10-18" @default.
• W2092183118 title "Serum Proinflammatory Mediators at Different Periods of Therapy in Patients With Multiple Myeloma" @default.
• W2092183118 cites W1484344085 @default.
• W2092183118 cites W1972678966 @default.
• W2092183118 cites W1988977449 @default.
• W2092183118 cites W1994169708 @default.
• W2092183118 cites W1999861949 @default.
• W2092183118 cites W2000697699 @default.
• W2092183118 cites W2019981138 @default.
• W2092183118 cites W2024884089 @default.
• W2092183118 cites W2051630963 @default.
• W2092183118 cites W2051743148 @default.
• W2092183118 cites W2055284972 @default.
• W2092183118 cites W2059086475 @default.
• W2092183118 cites W2059837358 @default.
• W2092183118 cites W2062738885 @default.
• W2092183118 cites W2063270450 @default.
• W2092183118 cites W2079007861 @default.
• W2092183118 cites W2101307567 @default.
• W2092183118 cites W2110105332 @default.
• W2092183118 cites W2112413552 @default.
• W2092183118 cites W2118526748 @default.
• W2092183118 cites W2123857513 @default.
• W2092183118 cites W2134828568 @default.
• W2092183118 cites W2312698295 @default.
• W2092183118 cites W2408849246 @default.
• W2092183118 cites W2410996055 @default.
• W2092183118 cites W2440867162 @default.
• W2092183118 doi "https://doi.org/10.1155/mi.2005.171" @default.
• W2092183118 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1526466" @default.
• W2092183118 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16106104" @default.
• W2092183118 hasPublicationYear "2005" @default.
• W2092183118 type Work @default.
• W2092183118 sameAs 2092183118 @default.
• W2092183118 citedByCount "29" @default.
• W2092183118 countsByYear W20921831182013 @default.
• W2092183118 countsByYear W20921831182016 @default.
• W2092183118 countsByYear W20921831182017 @default.
• W2092183118 countsByYear W20921831182018 @default.
• W2092183118 countsByYear W20921831182019 @default.
• W2092183118 countsByYear W20921831182020 @default.
• W2092183118 countsByYear W20921831182023 @default.
• W2092183118 crossrefType "journal-article" @default.
• W2092183118 hasAuthorship W2092183118A5008969241 @default.
• W2092183118 hasAuthorship W2092183118A5022059136 @default.
• W2092183118 hasAuthorship W2092183118A5032698656 @default.
• W2092183118 hasAuthorship W2092183118A5034207640 @default.
• W2092183118 hasAuthorship W2092183118A5035767817 @default.
• W2092183118 hasAuthorship W2092183118A5039810213 @default.
• W2092183118 hasAuthorship W2092183118A5077108549 @default.
• W2092183118 hasBestOaLocation W20921831181 @default.
• W2092183118 hasConcept C11988809 @default.
• W2092183118 hasConcept C126322002 @default.
• W2092183118 hasConcept C134018914 @default.
• W2092183118 hasConcept C164027704 @default.
• W2092183118 hasConcept C17991360 @default.
• W2092183118 hasConcept C203014093 @default.
• W2092183118 hasConcept C2776364478 @default.
• W2092183118 hasConcept C2776694085 @default.
• W2092183118 hasConcept C2776755627 @default.
• W2092183118 hasConcept C2776914184 @default.
• W2092183118 hasConcept C2778690821 @default.
• W2092183118 hasConcept C2779429289 @default.
• W2092183118 hasConcept C2780007613 @default.
• W2092183118 hasConcept C2780401358 @default.
• W2092183118 hasConcept C2780942790 @default.
• W2092183118 hasConcept C71924100 @default.
• W2092183118 hasConcept C74172505 @default.
• W2092183118 hasConcept C90924648 @default.
• W2092183118 hasConceptScore W2092183118C11988809 @default.
• W2092183118 hasConceptScore W2092183118C126322002 @default.
• W2092183118 hasConceptScore W2092183118C134018914 @default.
• W2092183118 hasConceptScore W2092183118C164027704 @default.
• W2092183118 hasConceptScore W2092183118C17991360 @default.
• W2092183118 hasConceptScore W2092183118C203014093 @default.
• W2092183118 hasConceptScore W2092183118C2776364478 @default.
• W2092183118 hasConceptScore W2092183118C2776694085 @default.
• W2092183118 hasConceptScore W2092183118C2776755627 @default.
• W2092183118 hasConceptScore W2092183118C2776914184 @default.
• W2092183118 hasConceptScore W2092183118C2778690821 @default.
• W2092183118 hasConceptScore W2092183118C2779429289 @default.
• W2092183118 hasConceptScore W2092183118C2780007613 @default.
• W2092183118 hasConceptScore W2092183118C2780401358 @default.
• W2092183118 hasConceptScore W2092183118C2780942790 @default.
• W2092183118 hasConceptScore W2092183118C71924100 @default.
• W2092183118 hasConceptScore W2092183118C74172505 @default.
• W2092183118 hasConceptScore W2092183118C90924648 @default.
• W2092183118 hasIssue "3" @default.

• next